When Grammy-nominated singer-songwriter Aloe Blacc bought COVID regardless of being vaccinated and boosted, he tried to fund analysis for a greater resolution. What he shortly discovered out? You can’t simply write a test in biotech. Regulators require a commercialization plan, and philanthropy doesn’t transfer science via medical trials or get you a license on college IP. Now, he’s bootstrapping a most cancers drug platform focusing on pancreatic most cancers, a illness that kills 90% of its sufferers, and deliberately ready to boost from his community till peer-reviewed papers could make his case.
On this episode of TechCrunch’s Fairness podcast, Rebecca Bellan sits down with Aloe Blacc to speak about what occurs when a creator decides to construct as an alternative of simply make investments, how Aloe is watching AI reshape each the biotech and music industries in actual time, and his ideas on who truly wins.
Hearken to the complete episode to listen to:
- How he’s navigating a world the place credibility is earned in information, not fame
- How a College of Houston molecule discovery platform may lower years off drug improvement timelines
- Why he thinks document labels, not artists or AI corporations, will in the end management the economics of AI-generated music
- What Suno taught him about prototyping, and why his subsequent album will nonetheless be recorded with stay musicians
Subscribe to Fairness on YouTube, Apple Podcasts, Overcast, Spotify and all of the casts. You can also observe Fairness on X and Threadsat @EquityPod.
